The German group found similar results and the CML IV study confirmed a significant difference in terms of 5-year OS between cases with BCR-ABL1/ABL1 ratio lower or higher than 10% at 3 months (94 vs. 87%) (30). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.